Product Reference
SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
| |
|
| Author |
Kai Fu,Michael J Corbley,Lihong Sun,Jessica E Friedman,Feng Shan,James L Papadatos,Donald Costa,Frank Lutterodt,Harry Sweigard,Scott Bowes,Michael Choi,P Ann Boriack-Sjodin,Robert M Arduini,Dongyu Sun,Miki N Newman,Xiamei Zhang,Jonathan N Mead,Claudio E Chuaqui,H-Kam Cheung,Xin Zhang,Mark Cornebise,Mary Beth Carter,Serene Josiah,Juswinder Singh,Wen-Cherng Lee,Alan Gill,Leona E Ling |
| Citation Information |
Arteriosclerosis, thrombosis, and vascular biology, 28: (2008) |
| Keywords |
Activin Receptors, Type I,Adenosine Triphosphate,Administration, Oral,Animals,Azabicyclo Compounds,Binding Sites,Carotid Artery Injuries,Cell Line,Fibroblasts,Fibrosis,Humans,Male,Myoblasts, Smooth Muscle,Protein Kinase Inhibitors,Protein-Serine-Threonine Kinases,Rats,Rats, Sprague-Dawley,Receptors, Transforming Growth Factor beta,Transforming Growth Factor beta |
| Related Products |
30-011 |
| Pub Med ID |
18202322 |
| |
|
Abstract
TGF-beta plays a significant role in vascular injury-induced stenosis. This study evaluates the efficacy of a novel, small molecule inhibitor of ALK5/ALK4 kinase, in the rat carotid injury model of vascular fibrosis.
